<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BUMINATE- albumin human injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1><span class="Bold">BUMINATE 20%, Albumin (Human), USP, 20% Solution</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_376e2060-7019-4424-aabe-b87f7e50035d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">BUMINATE 20% in 50 and 100 mL glass bottles is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 20 g of albumin and was prepared from human venous plasma using the Cohn <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and/or sodium hydroxide and stabilized with N-acetyltryptophan (0.016M) and sodium caprylate (0.016M). The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 20% is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> straw to an amber color.</p>
<p>The likelihood of the presence of viable <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses has been minimized by testing the plasma at three stages for the presence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses, by fractionation steps with demonstrated virus removal capacity and by heating the product for 10 hours at 60°C. This procedure has been shown to be an effective method of inactivating <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> virus in albumin solutions even when those solutions were prepared from plasma known to be infective.<span class="Sup">1-3</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_8e93bdb4-2bff-49f0-8323-1d71cd6b2743"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Albumin is responsible for 70-80% of the colloid osmotic pressure of normal plasma, thus making it useful in regulating the volume of circulating blood.<span class="Sup">4-6</span> Albumin is also a transport protein and binds naturally occurring, therapeutic and toxic materials in the circulation.<span class="Sup">5,6</span></p>
<p>BUMINATE 20% is osmotically equivalent to approximately four times its volume of human plasma.  When injected intravenously, 20% albumin will draw about three times its volume of additional fluid into the circulation within 15 minutes, except when the patient is markedly dehydrated.  This extra fluid reduces hemoconcentration and blood viscosity.  The degree and duration of volume expansion depends upon the initial blood volume.  In patients with decreased blood volume, the effect of infused albumin can persist for many hours; however, in patients with normal blood volume, the duration will be shorter.<span class="Sup">7-9</span></p>
<p>Total body albumin is estimated to be 350 g for a 70 kg man and is distributed throughout the extra cellular compartments; more than 60% is located in the extravascular fluid compartment.  The half-life of albumin is 15 to 20 days with a turnover of approximately 15 g per day.<span class="Sup">5</span></p>
<p>The minimum plasma albumin level necessary to prevent or reverse <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> is unknown.  Some investigators recommend that plasma albumin levels be maintained at approximately 2.5 g/dL.  This concentration provides a plasma oncotic pressure value of 20 mm Hg.<span class="Sup">4</span></p>
<p>BUMINATE 20% is manufactured from human plasma by the modified Cohn-Oncley <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol fractionation process, which includes a series of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-ethanol precipitation, centrifugation and/or filtration steps followed by pasteurization of the final product at 60 ± 0.5°C for 10 – 11 hours.  This process accomplishes both purification of albumin and reduction of viruses.</p>
<p><span class="Italics">In vitro</span> studies demonstrate that the manufacturing process for BUMINATE 20% provides for effective viral reduction.  These viral reduction studies, summarized in Table 1, demonstrate viral clearance during the manufacturing process for BUMINATE 20% using human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus, type 1 (HIV-1) both as a target virus and model for HIV-2 and other lipid-enveloped RNA viruses; bovine viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus (BVDV), a model for lipid-enveloped RNA viruses, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV); West Nile Virus (WNV), a target virus and model for other similar lipid-enveloped RNA viruses; pseudorabies virus (PRV), a model for other lipid-enveloped DNA viruses such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV); mice minute virus (MMV), models for non-enveloped DNA viruses such as human parvovirus B 19<span class="Sup">10</span>; and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A virus (HAV), a target virus and a model for other non-enveloped RNA viruses.</p>
<p>These studies indicate that specific steps in the manufacture of BUMINATE 20% are capable of eliminating/inactivating a wide range of relevant and model viruses.  Since the mechanism of virus elimination/inactivation by fractionation and by heating steps is different, the overall manufacturing process of BUMINATE 20% is effective in reducing viral load.</p>
<table width="100%">
<col width="23%">
<col width="11%">
<col width="18%">
<col width="11%">
<col width="11%">
<col width="10%">
<col width="16%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Other Albumin fractionation process steps (processing of cryo-poor plasma to Fraction I+II+III/II+III supernatant and processing of Fraction V suspension to Cuno 90LP filtrate) showed significant virus reduction capacity in <span class="Italics">in-vitro</span> viral clearance studies. These process steps also contribute to the overall viral clearance robustness of the manufacturing process. However, since the mechanism of virus removal is similar to that of  this particular process step, the viral inactivation data from other steps were not used in the calculation of the Mean Cumulative Reduction Factor.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>not determined</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Recent scientific data suggests that the actual human parvovirus B19 (B19V), is far more effectively inactivated by pasteurization than indicated by model virus data.<span class="Sup">10</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule"><td class="Botrule" align="center" colspan="7"><p class="First"><span class="Bold">Table 1 </span><br><span class="Bold">Summary of Viral Reduction Factor for Each Virus and Processing Step</span></p></td></tr>
<tr>
<td><p class="First"><span class="Bold">Process Step</span></p></td>
<td class="Botrule" align="center" colspan="6"><p class="First"><span class="Bold">Viral Reduction Factor (log<span class="Sub">10</span>)</span></p></td>
</tr>
<tr>
<td><p class="First">   </p></td>
<td class="Botrule" align="center" colspan="4"><p class="First"><span class="Bold">Lipid Enveloped</span></p></td>
<td class="Botrule" colspan="2"><p class="First"><span class="Bold">Non- Enveloped</span></p></td>
</tr>
<tr>
<td class="Botrule" rowspan="2"><p class="First">   </p></td>
<td class="Botrule" align="center" rowspan="2"><p class="First"><span class="Bold">HIV-1</span></p></td>
<td class="Botrule" align="center" colspan="2"><p class="First"><span class="Bold"><span class="Italics">Flaviviridae</span></span></p></td>
<td class="Botrule" align="center" rowspan="2"><p class="First"><span class="Bold">PRV</span></p></td>
<td class="Botrule" align="center" rowspan="2"><p class="First"><span class="Bold">HAV</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold"><span class="Italics">Parvoviridae</span></span></p></td>
</tr>
<tr>
<td class="Botrule" align="center"><p class="First"><span class="Bold">BVDV</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">WNV</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">MMV</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"> Processing of Fraction I+II+III/II+III supernatant to Fraction IV<span class="Sub">4</span> Cuno 70C filtrate<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule" align="center"><p class="First"> &gt;4.9 </p></td>
<td class="Botrule" align="center"><p class="First"> &gt;4.8 </p></td>
<td class="Botrule" align="center"><p class="First"> &gt;5.7 </p></td>
<td class="Botrule" align="center"><p class="First"> &gt;5.5 </p></td>
<td class="Botrule" align="center"><p class="First"> &gt;4.5 </p></td>
<td class="Botrule" align="center"><p class="First"> 3.0 </p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"> Pasteurization </p></td>
<td class="Botrule" align="center"><p class="First"> &gt;7.8 </p></td>
<td class="Botrule" align="center"><p class="First"> &gt;6.5 </p></td>
<td class="Botrule" align="center"><p class="First"> n.d.<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule" align="center"><p class="First"> &gt;7.4 </p></td>
<td class="Botrule" align="center"><p class="First"> 3.2 </p></td>
<td class="Botrule" align="center"><p class="First"> 1.6<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule"><p class="First"><span class="Bold">Mean Cumulative Reduction Factor, log<span class="Sub">10</span></span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">&gt;12.7</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">&gt;11.3</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">&gt;5.7</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">&gt;12.9</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">&gt;7.7</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">4.6</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_489a7469-bc54-409c-9070-ee6c6b08d5dd"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8bf3a883-dfd9-489b-91ef-c0b1cada837f"></a><a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span></h2>
<p class="First">The effectiveness of BUMINATE 20% in reversing <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> depends largely upon its ability to draw interstitial fluid into the circulation.  It is most effective with patients who are well hydrated.  When <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> is long-standing and <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> exists accompanied by adequate hydration or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, 20% albumin is preferable to 5% protein solutions.<span class="Sup">4,6  </span>Use 5% protein solutions or dilute 20% albumin with crystalloid solutions in the absence of adequate or excessive hydration.   Administer compatible red blood cells or whole blood as quickly as possible when blood volume deficit is the result of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_514e3261-754c-4842-b1d9-4955acc17682"></a><a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></h2>
<p class="First"><span class="Underline">General</span></p>
<p><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span> can result from one or more of the following:<span class="Sup">5</span></p>
<p>(1) Inadequate production (<span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, major injury, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, etc.)</p>
<p>(2) Excessive catabolism (<span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, major injury, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, etc.)</p>
<p>(3) Loss from the body (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, excessive renal excretion, burn exudates, etc.)</p>
<p>(4) Redistribution within the body (major surgery, various inflammatory conditions, etc.)</p>
<p>When albumin deficit is the result of excessive protein loss, the effect of albumin administration will be temporary unless the underlying disorder is reversed.  </p>
<p>There is no valid reason for use of albumin as an intravenous nutrient. In most cases, increased nutritional replacement of amino acids and/or protein with concurrent treatment of the underlying disorder will restore normal plasma albumin levels more effectively than albumin solutions. </p>
<p>Occasionally, <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> accompanying severe injuries, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> cannot be quickly reversed and nutritional supplements can fail to restore serum albumin levels.  BUMINATE 20% is indicated in these cases.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></span></p>
<p>An optimum regimen for the use of albumin, electrolytes and fluid in the early treatment of <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> has not been established; however, in conjunction with appropriate crystalloid therapy, BUMINATE 20% is indicated for treatment of oncotic deficits after the initial 24-hour period following <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">extensive burns</span> and to replace the protein loss which accompanies any severe burn.<span class="Sup">4,6</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Adult Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>)</span></p>
<p>A characteristic of <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span> is interstitial <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, which can be causally related to <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>.  20% albumin solution, is indicated for these cases when used with a diuretic.<span class="Sup">4</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span></span></p>
<p>BUMINATE 20% is indicated for treatment of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in patients with severe <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> who are receiving steroids and/or diuretics.</p>
<p><span class="Underline">Cardiopulmonary Bypass Surgery</span></p>
<p>BUMINATE 20% is indicated during cardiopulmonary bypass surgery as a component of the pump prime.<span class="Sup">4,6,12</span></p>
<p><span class="Underline">Hemolytic Disease of the Newborn (HDN)</span></p>
<p>BUMINATE 20% is indicated for infants with severe HDN to bind and detoxify unconjugated bilirubin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_0667aa3e-4272-4374-8090-f40c8b961f35"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<dl>
<dt>•</dt>
<dd>A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to albumin and any of the excipients</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></dd>
</dl>
<p class="First">Do not dilute with Sterile Water for Injection as this can cause <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in recipients. There exists a risk of potentially fatal <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> from the use of Sterile Water for Injection as a diluent for Albumin (Human). Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.</p>
<p>Do not administer to patients with chronic renal insufficiencies due to the potential for accumulations of aluminum.  Accumulations of aluminum in patients with chronic renal insufficiencies have led to toxic manifestations such as <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, vitamin D-refractory <span class="product-label-link" type="condition" conceptid="75924" conceptname="Osteodystrophy">osteodystrophy</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and severe progressive <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.<span class="Sup">11-13</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_0ff2009f-075e-4d52-b190-8875b9ae4523"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Allergic /<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></span></p>
<p>Suspicion of allergic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactic type reactions</span> requires immediate discontinuation of the injection. In case of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, implement standard medical treatment for <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p><span class="Bold">Transmission of Infectious Agents</span></p>
<p>BUMINATE 20% is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin.</p>
<p>All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product, should be reported by the physician, or other healthcare provider to Baxter Healthcare Corporation at 1-800-423-2862.  The physician should discuss the risks and benefits of this product with the patient.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_6ff09046-7a08-4c43-b1ac-75d3e289a912"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Certain components used in the packaging of this product contain natural rubber latex which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d090fdc3-62c1-4870-a028-8e636cda94c2"></a><a name="section-6.1"></a><p></p>
<h2>Hemodynamics</h2>
<p class="First">Closely monitor hemodynamic parameters after administering BUMINATE 20% for evidence of cardiac or <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, or increasing intracranial pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_25f9e6fe-cc0f-4dbd-9658-3d7974775368"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span>/Hemodilution</h2>
<p class="First">Administer BUMINATE 20% with caution in conditions where <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and its consequences or hemodilution could represent a special risk for the patient.  Examples include, but are not limited to, the following: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">hemorrhagic diathesis</span>, severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and renal  failure.</p>
<p>Adjust the rate of administration according to the solution concentration and the patient’s hemodynamic status.   Do not exceed 1 mL per min to patients with normal blood volume.  More rapid administration can cause circulatory overload and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.<span class="Sup">14   </span>Discontinueadministration at the first clinical signs of cardiovascular overload (e.g., <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, jugular venous <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, and abnormal elevations in systemic or central venous blood pressure).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_292624f2-7240-4c67-97b3-edc805aaab7f"></a><a name="section-6.3"></a><p></p>
<h2>Blood Pressure</h2>
<p class="First">Monitor blood pressure in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> patients and postoperative surgery patients resuscitated with BUMINATE 20% in order to detect rebleeding secondary to clot disruption.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_0d1da5c9-0339-41b2-8fc2-6109ac0a781c"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy–Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with BUMINATE 20%.  It is not known whether BUMINATE 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  BUMINATE 20% should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_6fffa83d-3a50-4c69-bb2c-0521775c36da"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether BUMINATE 20% is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when BUMINATE 20% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_e56ba8ff-f170-4eae-b6b4-740b7f2a3d78"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety of albumin solutions has been demonstrated in children provided the dose is appropriate for body weight, however, the safety of BUMINATE 20% has not been evaluated in pediatric use. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c748535f-9bf8-4c0a-a76a-8ed03f4538e7"></a><a name="section-6.7"></a><p></p>
<h2>Large Volumes</h2>
<p class="First">Monitor hemodynamic parameters.  Ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets, and erythrocytes) are available if comparatively large volumes are replaced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fb20d83d-08cb-4513-97b6-bc8b9f806f45"></a><a name="section-6.8"></a><p></p>
<h2>Electrolyte Status </h2>
<p class="First">Monitor electrolyte status and ensure appropriate steps are taken to restore or maintain the electrolyte balance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b2c4dc22-fa7e-4213-913d-070661ef1100"></a><a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS </h1>
<p class="First">No interaction studies have been performed with BUMINATE 20%.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_298a4429-ddd0-4951-904b-783cc66152bc"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0e5e1c45-0de1-48f8-98fe-5c2dcbcf003a"></a><a name="section-8.1"></a><p></p>
<h2>Adverse Reactions from Clinical Trials</h2>
<p class="First">There are no data available on adverse reactions from Baxter-sponsored clinical trials conducted with BUMINATE 20%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_09ef3ac4-37f2-4437-98ed-17413889f55b"></a><a name="section-8.2"></a><p></p>
<h2>Post-Marketing Adverse Reactions</h2>
<p class="First">The following adverse reactions have been reported in the post-marketing experience:  </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>,<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>,<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Bold">General Disorders and Administration Site Conditions: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_0360b422-6601-4a2d-a68c-b3cafa43aba9"></a><a name="section-9"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span> may occur if the dosage and rate of infusion are too high. [see <span class="Italics">Precautions: <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span>/Hemodilution</span>]</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_e09308aa-7647-4205-9636-9828eeb08349"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">BUMINATE 20% must be administered intravenously.</span></p>
<dl>
<dt>•</dt>
<dd>Do not use if turbid.  </dd>
<dt>•</dt>
<dd>Do not begin administration more than 4 hours after the container has been entered. </dd>
<dt>•</dt>
<dd>Monitor hemodynamic parameters in patients receiving BUMINATE 20% and check for the risk of <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and cardiovascular overload.[see <span class="Italics">Precautions</span>] <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span> can occur if the dosage and rate of infusion are not adjusted, giving consideration to the solution concentration and the patient’s clinical status.</dd>
<dt>•</dt>
<dd>Do not dilute with Sterile Water for Injection as this can cause <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in recipients [see <span class="Italics">Contraindications</span>].</dd>
<dt>•</dt>
<dd>Do not mix with other medicinal products including blood and blood components.  BUMINATE 20% can be used concomitantly with other parenterals such as whole blood, plasma, saline, glucose or sodium lactate when deemed medically necessary.  The addition of four volumes of normal saline or 5% glucose to 1 volume of BUMINATE 20% gives a solution, which is approximately isotonic and isosmotic with citrated plasma. The volume of the total dose and the rate of infusion depend on the patient’s condition and response.</dd>
<dt>•</dt>
<dd>Do not mix with protein hydrolysates or solutions containing alcohol since these combinations can cause the proteins to precipitate.</dd>
<dt>•</dt>
<dd>Do not add supplementary medication.</dd>
<dt>•</dt>
<dd>Record the name and batch number of the product to maintain a link between the patient and the product.</dd>
<dt>•</dt>
<dd>Discard unused portion.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ccc77372-b100-465e-9d1b-8715d7deb4d7"></a><a name="section-10.1"></a><p></p>
<h2>Recommended Dosages</h2>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">Hypovolemic Shock</span></span></span></p>
<p>The dosage of BUMINATE 20% must be individualized.  Initial dosage range for older adults is 125 to 250 mL and children 3 to 6 mL per kilogram of body weight.  Repeat after 15 to 30 minute intervals if the response is not adequate.</p>
<p>Upon administration of additional albumin or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> occurs; hemodilution and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> can occur.  Supplemental administration of compatible red blood cells or compatible whole blood may be required to treat this condition.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></span></span></p>
<p>The optimal therapeutic regimen for administration of crystalloid and colloid solutions after <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">extensive burns</span> has not been established.  Determine the appropriate dose according to the patient’s condition and response to treatment when BUMINATE 20% is administered after the first 24 hours following <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span> is usually accompanied by a hidden extravascular albumin deficiency of equal magnitude.  Consider total body albumin deficit when determining the amount of albumin necessary to reverse the <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>.  Calculate the body albumin compartment to be 80 to 100 mL per kg of body weight when using the patient’s serum albumin concentration to estimate the deficit.<span class="Sup">5,6</span>  Do not exceed a daily dose of 2 g of albumin per kilogram of body weight.</p>
<p><span class="Bold"><span class="Italics">Hemolytic Disease of the Newborn</span></span></p>
<p>Administer BUMINATE 20% prior to or during exchange transfusion at a dose of 1g per kilogram body weight.<span class="Sup">15</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1d1a5727-03ef-4de2-a10a-07865e9ab5a5"></a><a name="section-10.2"></a><p></p>
<h2>Preparation for Administration</h2>
<p class="First">Visually inspect parenteral drug products for particulate matter and discoloration prior to administration.  BUMINATE 20% is a transparent or slightly opalescent solution, which may have a greenish tint or may vary from a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> straw to an amber color.  Do not use unless solution is clear of particulate matter and seal is intact.</p>
<p>1. Remove cap from bottle to expose center portion of rubber stopper.</p>
<p>2. Clean stopper with germicidal solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a9a1335e-85e4-46e7-9cfe-f281489baeb0"></a><a name="section-10.3"></a><p></p>
<h2>Administration</h2>
<p class="First">Follow directions for use printed on the administration set container.  Make certain that the administration set contains an adequate filter (15-micron or smaller).  Insert the administration set spike straight through the center of the marked ring on the vial stopper.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_47de43ce-8e13-4ae0-8e0c-afd7444a540e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">BUMINATE 20% is supplied in glass bottles:</p>
<dl>
<dt>•</dt>
<dd>50 mL  NDC 0944-0482-01 </dd>
<dt>•</dt>
<dd>100 mL  NDC 0944-0482-02 </dd>
</dl>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_35c2c27f-baa2-4411-a3de-612de6b0e809"></a><a name="section-12"></a><p></p>
<h1>STORAGE</h1>
<p class="First"><span class="Bold">Room temperature</span>: Do not exceed 30°C (86°F).  Avoid freezing.</p>
<p>Stability testing for BUMINATE 20% showed that aluminum concentration increased over time reaching levels that could exceed 1000 ppb over the shelf life of the product.[see <span class="Italics">Contraindications</span>)</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_9822b55d-ab7b-4e33-9e95-d50c6109ebee"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Cai K, Gierman T,<span class="Italics"> et al</span>: Ensuring the Biologic Safety of Plasma-Derived Therapeutic Proteins. Department of Preclinical Research and Pathogen Safety, Bayer HealthCare LLC, North Carolina, USA. Biodrugs 19(2): 79-96 2005.</dd>
<dt>2.</dt>
<dd>Gerety RJ, Aronson DL: Plasma derivatives and <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>. Transfusion 22:347 351, 1982</dd>
<dt>3.</dt>
<dd>Burnouf T, Padilla A, Current strategies to prevent transmission of prions by human plasma derivatives. TransfusionClinique et Biologique 13: 320-328, 2006</dd>
<dt>4.</dt>
<dd>Tullis JL: Albumin, 1. Background and use, and 2. Guidelines for clinical use. JAMA 237:355-360, 460-463, 1977</dd>
<dt>5.</dt>
<dd>Peters T Jr: Serum albumin, in The Plasma Proteins, 2nd ed , Vol 1. Putnam FW (ed). New York, Academic Press, 1975, pp 133-181</dd>
<dt>6.</dt>
<dd>Finlayson JS: Albumin products. Semin Thromb Hemostas 6:85-120, 1980</dd>
<dt>7.</dt>
<dd>Haynes G, Navickis R, Wilkes M, Albumin administration – what is the evidence of clinical benefit? A systematic review of randomized controlled trials. European Journal of Anesthesiology 20:771-793 2003</dd>
<dt>8.</dt>
<dd>Mendez, C, McClain C, Marsano L <span class="Italics">et al</span>, Albumin Therapy in Clinical Practice. Nutrition in Clinical Practice 20 No. 3:314-320, June 2005</dd>
<dt>9.</dt>
<dd>Quinlan G, Martin G, Evans T, Albumin: Biochemical Properties and Therapeutic Potential. HEMATOLOGY Vol 14, No. 6 1211-1219 2005</dd>
<dt>10.</dt>
<dd>J. Blümel <span class="Italics">et al</span>., Inactivation of Parvovirus B19 During Pasteurization of Human Serum Albumin. Transfusion 42:1011-1018 , 2002</dd>
<dt>11.</dt>
<dd>Milliner DS, Shenaberger JH, Shuman P, <span class="Italics">et al</span>: Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. N Engl J Med 312:165-7,1985</dd>
<dt>12.</dt>
<dd>Ott SM, Maloney NA, Klein GL, <span class="Italics">et al</span>: Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med 98:910-4,1983</dd>
<dt>13.</dt>
<dd>Wills MR, Savory J: Aluminum <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>: dialysis <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anaemia</span>. Lancet 2:29-34,1983</dd>
<dt>14.</dt>
<dd>Grocott, Michael P.W., Mythen, Michael G., and Gan, Tong J. Perioperative Fluid Management and Clinical Outcomes in Adults. Anesth Analg. 2005;100:1100</dd>
<dt>15.</dt>
<dd>Tsao YC, Yu VYH: Albumin in management of neonatal hyperbilirubinaemia.  Arch Dis Childhood 47:250-256, 1972</dd>
</dl>
<p class="First">Baxter Healthcare Corporation</p>
<p>Westlake Village, CA 91362 USA</p>
<p>U.S. License No. 140<br></p>
<p>To enroll in the confidential, industry-wide Patient Notification System, call 1-888-UPDATE U (1-888-873-2838).<br></p>
<p>Baxter and Buminate are trademarks of Baxter International, Inc.</p>
<p>Revised February 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8f160b2c-3fe6-4cb9-bfa4-8a57d0ebc87d"></a><a name="section-14"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id1415665314"></a><img alt="Buminate 20% 50 mL bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6ad848db-2867-42e1-81ae-c435e44c37e2&amp;name=image-01.jpg"><p class="MultiMediaCaption">Buminate 20% 50 mL bottle label </p>
</div>
<p class="First">Buminate 20% 50 mL bottle label </p>
<p>50 mL (10 g protein)</p>
<p>NDC 0944-0482-01</p>
<p><span class="Bold">Albumin (Human), USP, 20% Solution</span></p>
<p><span class="Bold">BUMINATE 20%</span></p>
<p>This bottle contains 10 g albumin from venous plasma in buffered diluent and is osmotically equivalent to 200 mL of normal human plasma. It has been stabilized with sodium caprylate and N-acetyltryptophan and heated for 10 hours at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative. Store at room temperature, not to exceed 30°C (86°F). Avoid freezing to prevent damage to the bottle. See attached directions for use. <span class="Bold">Caution:</span> In patients with marked <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> additional fluids must accompany or follow administration of this product. <span class="Bold">Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered.</span> Single dose container. Discard partially used bottle. The patient and physician should discuss the risks and benefits of this product.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>US. License No. 140<br></p>
<div class="Figure">
<a name="id-335994332"></a><img alt="Buminate 20% 100 mL bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6ad848db-2867-42e1-81ae-c435e44c37e2&amp;name=image-02.jpg"><p class="MultiMediaCaption">Buminate 20% 100 mL bottle label </p>
</div>
<p>Buminate 20% 100 mL bottle label </p>
<p>100 mL (10 g protein)</p>
<p>NDC 0944-0482-01</p>
<p><span class="Bold">Albumin (Human), USP, 20% Solution</span></p>
<p><span class="Bold">BUMINATE 20%</span></p>
<p>This bottle contains 20 g albumin from venous plasma in buffered diluent and is osmotically equivalent to 400 mL of normal human plasma. It has been stabilized with sodium caprylate and N-acetyltryptophan and heated for 10 hours at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative. Store at room temperature, not to exceed 30°C (86°F). Avoid freezing to prevent damage to the bottle. See attached directions for use. </p>
<p><span class="Bold">Caution: </span>In patients with marked <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> additional fluids must accompany or follow administration of this product. <span class="Bold">Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered. </span>Single dose container. Discard partially used bottle. The patient and physician should discuss the risks and benefits of this product.<br></p>
<p><span class="Bold">Rx Only <br></span></p>
<p><span class="Bold">Baxter Healthcare Corporation </span></p>
<p>Westlake Village, CA 91362 USA</p>
<p>US. License No. 140</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BUMINATE 		
					</strong><br><span class="contentTableReg">albumin human injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-0482</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALBUMIN HUMAN</strong> (ALBUMIN HUMAN) </td>
<td class="formItem">ALBUMIN HUMAN</td>
<td class="formItem">0.2 g  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CAPRYLATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETYLTRYPTOPHANATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-0482-01</td>
<td class="formItem">50 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0944-0482-02</td>
<td class="formItem">100 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Export only</td>
<td class="formItem"></td>
<td class="formItem">03/17/1954</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BAXTER HEALTHCARE CORPORATION</td>
<td class="formItem"></td>
<td class="formItem">085206634</td>
<td class="formItem">MANUFACTURE(0944-0482)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6ad848db-2867-42e1-81ae-c435e44c37e2</div>
<div>Set id: 6ad848db-2867-42e1-81ae-c435e44c37e2</div>
<div>Version: 2</div>
<div>Effective Time: 20141022</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
